Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06641544 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

Name: The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer — clinical trial record (NCT06641544)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IFANS

StatusRecruiting

PhasePhase 4

SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Started2024-10-17

View on ClinicalTrials.gov ↗

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

247 trials monitored

See 2 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrent/metastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy, hoping to have better clinical benefits and provide a new treatment mode for targeted treatment.

Trial Details

NCT Number	NCT06641544
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Metastatic Breast Cancer
Enrollment	200 participants
Start Date	2024-10-17
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-10-15